



Potiga[®] (ezogabine) – Drug discontinuation

- On July 5, 2017, [GlaxoSmithKline \(GSK\) announced](#) the permanent discontinuation and market withdrawal of [Potiga \(ezogabine\)](#) tablets due to the limited use of the medicine.
 - The discontinuation of Potiga was not due to any quality, efficacy, or safety concerns.
 - Wholesalers and pharmacies should stop distribution, immediately quarantine, and return all units of product.
- In August 2016, [GSK announced](#) that Potiga would no longer be commercially available after June 30, 2017.
- Healthcare providers are advised to seek alternative medicines for existing patients as soon as possible.
- Potiga is a Schedule V controlled substance indicated as adjunctive treatment of partial-onset seizures in patients aged 18 years and older who have responded inadequately to several alternative treatments and for whom the benefits outweigh the risk of retinal abnormalities and potential decline in visual acuity.
- Potiga carries a boxed warning for retinal abnormalities and potential vision loss.
- For assistance or questions about the discontinuation of Potiga or the withdrawal process, contact Stericycle at **1-855-544-4821**.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.